

ORIGINAL ARTICLE

Asthma and Lower Airway Disease

Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma

Jaco Voorham¹ | Xiao Xu² | David B. Price^{1,3}  | Sarowar Golam⁴ | Jill Davis⁵ | Joanna Zhi Jie Ling¹ | Marjan Kerkhof¹ | Mandy Ow¹ | Trung N. Tran²

¹Observational and Pragmatic Research Institute, Singapore, Singapore

²AstraZeneca, Gaithersburg, Maryland

³Centre for Academic Primary Care, University of Aberdeen, Aberdeen, UK

⁴AstraZeneca, Gothenburg, Sweden

⁵AstraZeneca, Wilmington, Delaware

Correspondence: David B. Price, FRCGP, Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZD, UK (dprice@opri.sg).

Funding information

This study was funded by AstraZeneca.

Abstract

Background: Although systemic corticosteroid (SCS) treatment, irrespective of duration or dosage, is associated with adverse outcomes for patients with asthma, the longitudinal effects of this treatment on adverse outcomes, healthcare resource utilization (HCRU), and healthcare costs are unknown.

Methods: We identified patients initiating intermittent or long-term SCS who were diagnosed with active asthma from UK general practice with linked secondary care data. Control (non-SCS) patients were matched by sex and index date with those initiating SCS. Minimum baseline period was 1 year prior to index date; minimum follow-up duration was 2 years post-index date. Cumulative incidence of SCS-associated adverse outcomes and associated HCRU and costs were compared between SCS and non-SCS patient groups and among average SCS daily exposure categories. Associations between exposure and annualized HCRU and costs were assessed, adjusted for confounders.


Results: Analyses included 9413 matched pairs. Median (interquartile range) follow up was as follows: SCS group: 7.1 (4.1-11.8) years; control group: 6.4 (3.8-10.0) years. Greater SCS dosages were correlated with greater cumulative incidence. For example, patients with type 2 diabetes receiving an average daily dosage of ≥ 7.5 mg had a 15-year cumulative incidence (37.5%) that was 1.5-5 times greater than those receiving lower dosages. HCRU and costs increased annually for SCS patients but not for non-SCS patients. Increases in all-cause adverse outcome (excluding asthma)-associated HCRU and costs were dose-dependent.

Conclusions: Over the long term, adverse outcomes associated with SCS initiation were relatively frequent and costly, with a positive dosage-response relationship with SCS exposure.

KEYWORDS

adverse outcomes, asthma, healthcare costs, healthcare resource utilization, systemic corticosteroids

Association of systemic corticosteroid exposure with mean annualized all-cause adverse outcome-associated (excluding asthma) healthcare resource utilization and costs



GRAPHICAL ABSTRACT

A greater cumulative incidence of adverse outcomes is correlated with greater systemic corticosteroid dosage for patients with asthma. Patients with asthma receiving systemic corticosteroids experience increases in annual health care resource utilization and costs, while those not receiving systemic corticosteroids do not. A dose-dependent increase in all-cause adverse outcome (excluding asthma)-associated annual health care resource utilization and costs occurs for patients with asthma receiving systemic corticosteroids.

1 | INTRODUCTION

Frequent short- or long-term corticosteroid use is associated with substantial adverse effects, including osteoporosis, peptic ulcers, cataracts, adrenal suppression, weight gain, hyperglycemia, hypertension, mood problems, and diabetes.¹⁻⁴ For example, Iribarren et al² reported the risks of coronary heart disease and all-cause mortality increased 2.5- and 2.6-fold, respectively, for patients with asthma compared with matched controls. This was driven by asthma-associated oral corticosteroid (OCS) use. In addition, the increased risk of adverse effects is dependent on corticosteroid dosage.^{2,5-8} Dalal et al⁸ found that long-term corticosteroid users (≥ 6 months) with low- (<5 mg/day), medium- (≥ 5 -10 mg/day), and high-dosage (>10 mg/day) exposure had, respectively, a 2.5-, 2.95-, and 3.32-fold greater adjusted relative risk of developing any steroid-related complication compared with steroid nonusers.

However, all previous studies had a relatively short baseline period that prevented true identification of systemic corticosteroid (SCS) initiators and, consequently, the study of longitudinal effects of SCS use from its initiation on adverse outcomes.¹⁻⁸ Furthermore, the longest follow-up period in previous studies was only up to 4 years, prohibiting the study of long-term impact of corticosteroid use on adverse outcomes. There are limited data available on the longitudinal impact of SCS exposure on healthcare systems, although the effect of SCS use on short-term healthcare resource utilization (HCRU) and associated costs has begun to be reported in the literature.^{8,9} In an analysis of adverse drug events (ADEs) in hospitals, Weiss and colleagues⁹ found corticosteroid use to be among the top

three causes of ADEs associated with hospital admission in the United States. Using a commercial database in the United States, Dalal et al⁸ found adjusted annual, incremental, steroid-related complication costs of \$2670, \$4639, and \$9162 (2014 US \$) over a 1.5-year median follow-up period for long-term low-, medium-, and high-dosage steroid users, respectively, compared with nonusers.

In this study, we compared the long-term incremental risks of adverse outcomes and their associated HCRU and costs for patients with asthma who did and did not initiate SCS (parenteral corticosteroid or OCS) and who had complete primary and secondary HCRU data. Furthermore, we explored how healthcare costs changed over time.

2 | METHODS

Additional details regarding the methods for cost estimations, measures and definitions, and statistical analyses are contained in the Appendices A-D, Tables S1-S6.

2.1 | Data source

We conducted a matched, historical cohort study using data from using the Clinical Practice Research Datalink (CPRD) database. The CPRD contains longitudinal data from 5 million active medical records from more than 600 subscribing practices throughout the United Kingdom. The CPRD data set contains patient records from June 1994 through January 2015, with 39% of patient data linked to Hospital Episode Statistics (HES), a data warehouse containing

TABLE 1 Demographics and baseline clinical characteristics of HCRU analysis cohort (overall SCS population)

Variable	SCS (n = 9413)	Non-SCS (n = 9413)	SMD (%)
Sex (male), n (%)	3268 (34.7)	3268 (34.7)	0.0
Age categories (years), n (%)			
18-40	3284 (34.9)	4890 (51.9)	28.6
41-60	3468 (36.8)	2593 (27.5)	
61-80	2378 (25.3)	1618 (17.2)	
>80	283 (3.0)	312 (3.3)	
BMI (kg/m ²), closest in 5 years prior, categorized, n (%)			
N (% nonmissing)	6511 (69.2)	6757 (71.8)	19.2
<18.5	140 (2.2)	183 (2.7)	
18.5-<25	2180 (33.5)	2816 (41.7)	
25-<30	2127 (32.7)	2092 (31.0)	
≥30	2064 (31.7)	1666 (24.7)	
Uncontrolled asthma, ^{a,b} n (%)	2863 (30.4)	1253 (13.3)	42.3
Severe asthma year prior, ^{b,c} n (%)	3794 (40.3)	2043 (21.7)	41.1
Hospitalization with asthma year prior, ^{b,d} n (%)	106 (1.1)	35 (0.4)	8.8
A&E with asthma year prior, ^{b,e} n (%)	71 (0.8)	32 (0.3)	5.6
High-dosage ICS year prior, ^f n (%)	582 (6.2)	365 (3.9)	10.6
SCS refills per year, ^g n (%)			
<1	2342 (28.4)	NA	NA
1-<2	2777 (33.7)	NA	NA
2-<3	1443 (17.5)	NA	NA
3-<4	694 (8.4)	NA	NA
4-<7	636 (7.7)	NA	NA
≥7	348 (4.2)	NA	NA
Hypertension diagnosis, ^h n (%)	1628 (17.3)	1325 (14.1)	8.9
Depression diagnosis, ^h n (%)	2842 (30.2)	2436 (25.9)	9.6
Peptic ulcer diagnosis, ^h n (%)	200 (2.1)	155 (1.6)	3.5
Dyslipidemia diagnosis or elevated lipids, ^{h,i} n (%)	1234 (13.1)	1065 (11.3)	5.5
Type 2 diabetes mellitus diagnosis or 2x HbA1c ≥6.5%, ^h n (%)	370 (3.9)	458 (4.9)	4.6
Cardio-cerebrovascular disease (MI, HF, CVA) diagnosis, ever prior, n (%)	382 (4.1)	364 (3.9)	1.0
MI diagnosis	165 (1.8)	144 (1.5)	1.8
HF diagnosis	95 (1.0)	119 (1.3)	2.4
CVA diagnosis	162 (1.7)	167 (1.8)	0.4
Glaucoma diagnosis, ever prior, n (%)	114 (1.2)	106 (1.1)	0.8
Sleep apnea diagnosis, ever prior, n (%)	23 (0.2)	19 (0.2)	0.9
Cataract diagnosis or surgery, ever prior, n (%)	327 (3.5)	303 (3.2)	1.4
Osteoporosis diagnosis, ever prior, n (%)	145 (1.5)	121 (1.3)	2.2

(Continues)

TABLE 1 (Continued)

Variable	SCS (n = 9413)	Non-SCS (n = 9413)	SMD (%)
Renal impairment, eGFR-based stage, closest prior, n (%)			
Stage 3a to Stage 5, eGFR <60	933 (9.9)	807 (8.6)	
Pneumonia diagnosis, year prior, n (%)	50 (0.5)	25 (0.3)	4.2
Charlson comorbidity index, new weights, n (%) ¹⁵			
0-4	3881 (41.2)	3852 (40.9)	
5-8	4304 (45.7)	4400 (46.7)	
9-12	329 (3.5)	315 (3.3)	
13-16	386 (4.1)	308 (3.3)	
≥17	513 (5.4)	538 (5.7)	

A&E, accident and emergency; BMI, body mass index; CVA, cerebrovascular accident; eGFR, estimated glomerular filtration rate; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; GINA, Global Initiative for Asthma; HbA1c, glycosylated hemoglobin; HCRU, healthcare resource utilization; HES, Health Episode Statistics database; HF, heart failure; ICS, inhaled corticosteroids; IQR, interquartile range; LDL, low-density lipoprotein cholesterol; MI, myocardial infarction; NA, not applicable; SCS, systemic corticosteroids; SD, standard deviation; SMD, standardized mean differences; TC, total cholesterol; TG, triglycerides.

^aUncontrolled asthma defined as either poor symptom control (either Asthma Control Questionnaire score >1.5, Asthma Control Test score <20, or “not well control” based on National Asthma Education and Prevention Program or GINA guidelines), frequent severe exacerbations requiring ≥2 bursts of SCS for >3 days in the previous year, serious exacerbation requiring at least one hospitalization, intensive care unit stay, or mechanical ventilation in the previous year, or airflow limitation (prebronchodilator FEV₁ <80% predicted in the presence of FEV₁/FVC less than lower limit of normal).

^bBased on HES data.

^cSevere asthma defined as GINA Step 4/5 or uncontrolled asthma.

^dHospitalization with asthma/lower respiratory code on same day.

^eA&E with asthma/lower respiratory code on same day.

^fHigh-dosage ICS defined as >500 µg/day fluticasone equivalent.

^gBased on follow-up period, N = 8240.

^hAny prior diagnosis ever.

ⁱDefined as TC >6.5, LDL >4, or TG ≥2.3.

complete and reliable information on inpatient hospital admissions, with linkage available from April 1997 through February 2016.¹⁰ CPRD also includes information from general practice (GP) visits. Public health researchers have used CPRD, formerly known as the General Practice Research Database, since 1987.¹¹ This study involved anonymized patient data that did not require ethics board approval, and was approved by the CPRD Independent Scientific Advisory Committee (reference number 17_002).

2.2 | Study design and patients

The study used a minimum 1-year baseline period and a minimum 2-year outcome (follow-up) period. The index date was the date of the first recorded prescription for a parenteral corticosteroid or OCS in the SCS arm, whereas for the non-SCS arm, it was the nearest GP visit to the matched-case index date. We matched non-SCS patients to SCS patients 1:1 by sex, availability of HES linkage, and index date. SCS

dosages were standardized into prednisolone equivalents (Table S3). To account for all HCRU outcomes, we included only the subset of unbroken matched pairs of active asthma patients with HES linkage in the final study population.¹⁰ We followed patients in both arms from the index date to the end of follow-up (ie, death, leaving the primary care practice, end of available records, or last date of extraction).

Patients in the SCS arm were ≥ 18 years old at first SCS prescription and had ≥ 1 SCS prescription within 18 months after first SCS prescription. Patients could not have a diagnosis of adrenal insufficiency/Addison's disease at any time, diagnosis of cancer 5 years before or 3 months after index date, or tamoxifen prescriptions for breast cancer at any time.

To evaluate the impact of SCS on the onset of an individual adverse outcome of interest, we removed patients having the individual adverse outcome of interest before the index date. Then, we removed patients who were left without a paired counterpart. As such, the analysis samples for the different SCS-related risk cohorts were dissimilar. Adverse outcomes evaluated are listed in Table S4. Given that asthma-related costs are highly driven by disease severity and not necessarily by SCS-associated adverse outcomes, we reported HCRU and costs associated with all-cause (Table S5) adverse outcomes excluding asthma and those associated with asthma (defined as reported with an asthma or lower respiratory disease code) separately. Inclusion of asthma-related costs in all-cause adverse outcome-associated costs would make the data very difficult to interpret.

2.3 | Statistical analyses

HCRU and associated costs were assessed annually, and annual averages for the entire follow-up period were calculated. We estimated HCRU-associated all-cause and cause-specific costs (2016 £) by multiplying HCRU outcomes by the estimated unit costs associated with each HCRU outcome from the Personal Social Services Research Unit,¹² National Health Service reference costs,¹³ and the Dictionary of Medicines and Devices browser.¹⁴ Prescription cost was obtained by multiplying cost by amount prescribed. Annualized HCRU and healthcare costs were reported.

We used generalized estimating equations with cluster-robust standard errors, log link, and gamma distribution to estimate the effect of SCS initiation on annualized HCRU or costs found by bootstrapping using 1000 random samples taken, with replacement, and adjusted for potential confounders. Besides reporting on adjusted mean, we also compared SCS and non-SCS patients using incidence rate ratio (IRR) for resources and cost ratios for cost with a 95% CI. Age and sex were used as forced covariates, and the remaining covariates were selected based on their incremental bias potential.

3 | RESULTS

Of 24 117 matched pairs of asthma patients, 16 623 pairs came from the CPRD database. Of these, the patients with an HES linkage were selected, and the ones who lost their matched pair were

removed, resulting in 9413 total matched pairs that were included in all analyses of this study. A comparison of baseline characteristics showed that the subset of patients with available HES linkage was not meaningfully different from the subset of patients without HES linkage (data not shown).

Of patients included in this study, fewer than 10% had < 2 years and half had ≥ 8 years of medical record history available before the index date. Patients had an average of 8.6 years of follow-up (median [interquartile range {IQR}]: 7.1 [4.1-11.8]) in the SCS arm and an average of 7.7 years (median [IQR]: 6.4 [3.8-10.0]) in the non-SCS arm. In the SCS arm, 11.9% of patients had ≥ 4 refills of SCS per year; median daily dosage of the SCS prescribed was 10 mg, and median total dosage prescribed in one prescription was 200 mg.

Female patients comprised two-thirds (65.3%) of patients (Table 1). SCS-initiating patients were older than patients in the non-SCS arm (49 vs 43 years) and had worse lung function (percent predicted normal 72.8% vs 82.9%) (Table 1). In addition, a greater percentage of SCS-initiating patients had severe asthma (defined as Global Initiative for Asthma [GINA] Step 4/5 OR uncontrolled asthma) based on HES linkage (40.3% vs 21.7%) and prior-year hospitalization for asthma (1.1% vs 0.4%) than control patients. The baseline comorbidities were similar between the arms (standardized mean differences $< 10\%$).

3.1 | Cumulative incidence of adverse outcomes

To assess the occurrence of adverse outcomes associated with SCS exposure, we examined cumulative incidence among patients who had no recorded history of that specific outcome at baseline. Regardless of SCS dosage, 15-year cumulative incidence was higher in the SCS arm than in the non-SCS arm (eg, renal impairment: 27.9% vs 12.5%; type 2 diabetes: 9.5% vs 5.6%, respectively; Figure S1). Other adverse outcomes followed a similar trend. The 15-year cumulative incidences in the SCS vs non-SCS arm, respectively, were as follows: pneumonia, 11.3% vs 3.5%; cataracts, 11.0% vs 4.4%; cerebrovascular accident, 10.0% vs 5.1%; cardio-cerebrovascular disease, 9.9% vs 3.6%; osteoporosis, 8.0% vs 2.0%; myocardial infarction, 7.3% vs 2.8%; heart failure, 3.6% vs 1.1%; and glaucoma, 3.4% vs 1.7%.

Greater SCS dosages were also correlated with greater cumulative incidence. For example, for type 2 diabetes, SCS patients with an average daily dosage of ≥ 7.5 mg had a 15-year cumulative incidence of 37.5%, which was 1.5-5 times greater than that of patients receiving < 0.5 mg/day (cumulative incidence, 7.0%), 0.5- < 2.5 mg/day (11.3%), 2.5- < 5.0 mg/day (16.3%), and 5.0- < 7.5 mg/day (25.0%) (Figure S2). For patients with an average exposure of 2.5-5 mg/day, which corresponds to three steroid bursts per year, in a 5-, 10-, and 15-year period, 5%, 10%, and 16% of these patients would develop type 2 diabetes, respectively (Table S7). Similar trends were observed for all other adverse outcomes (data not shown).

3.2 | Healthcare resource utilization

SCS-initiated patients with asthma had substantially greater frequency of all-cause adverse outcome-associated (excluding

TABLE 2 Mean (SD) annualized HCRU for all-cause adverse outcomes and asthma

HCRU	No SCS n = 9413	Overall SCS n = 9413	Mean average daily exposure (mg)					
			>0-<0.5 n = 5152	0.5-<2.5 n = 3497	2.5-<5.0 n = 436	5.0-<7.5 n = 174	7.5-<15.0 n = 134	≥15.0 n = 20
All-cause adverse outcome-associated HCRU (excluding asthma-related)								
General practitioner visits	9.18 (7.76)	12.42 (8.73)	10.55 (7.90)	13.79 (8.87)	17.54 (10.65)	19.81 (12.66)	20.09 (12.15)	28.45 (17.17)
Specialist visits	1.17 (1.94)	1.47 (2.91)	1.29 (2.15)	1.55 (2.37)	1.93 (2.92)	2.54 (4.35)	2.72 (3.59)	3.10 (5.90)
Hospitalizations	0.32 (1.94)	0.40 (0.97)	0.33 (0.72)	0.44 (0.59)	0.68 (1.04)	0.78 (2.11)	0.84 (1.04)	1.48 (2.01)
Accident and emergency visits	0.15 (0.97)	0.20 (0.97)	0.18 (0.72)	0.23 (0.59)	0.23 (0.63)	0.21 (0.40)	0.26 (0.69)	0.90 (1.79)
Prescriptions	10.08 (23.28)	14.04 (24.26)	11.37 (23.69)	15.32 (23.65)	23.09 (24.85)	30.82 (37.46)	28.38 (22.23)	39.42 (31.75)
Asthma-related HCRU								
General practitioner visits	1.34 (1.94)	2.65 (1.94)	2.01 (1.44)	3.21 (1.77)	4.23 (2.92)	4.44 (3.30)	4.37 (3.24)	6.26 (3.53)
Specialist visits	0.07 (0.97)	0.23 (0.97)	0.12 (0.72)	0.26 (1.18)	0.70 (1.67)	0.91 (4.35)	1.13 (1.74)	3.10 (6.89)
Hospitalizations	0.00 (0.00)	0.02 (0.00)	0.01 (0.00)	0.03 (0.00)	0.06 (0.21)	0.04 (0.13)	0.21 (1.39)	0.33 (0.45)
Accident and emergency visits	0.00 (0.00)	0.01 (0.00)	0.01 (0.00)	0.01 (0.00)	0.02 (0.21)	0.00 (0.00)	0.04 (0.35)	0.05 (0.22)
Prescriptions	5.35 (5.82)	10.61 (9.70)	7.85 (7.18)	12.59 (9.46)	19.01 (13.36)	21.31 (15.43)	21.23 (15.05)	25.62 (17.62)

HCRU, healthcare resource utilization; SCS, systemic corticosteroids; SD, standard deviation.

asthma-related) HCRU and asthma-related HCRU than patients without SCS initiation (Table 2). The adjusted IRRs (95% CI) shown in Figure 1A for SCS initiation vs non-SCS were 1.22 (1.19-1.25) for GP visits, 1.12 (1.06-1.18) for specialist visits, 1.14 (1.06-1.23) for hospitalization, 1.26 (1.16-1.36) for accident and emergency (A&E) attendances, and 1.35 (1.27-1.43) for primary care prescriptions. All HCRU types showed a positive dosage-response relationship with the mean number of adverse outcome-associated resources used, except the A&E attendances (Figure 1B, reference lowest dosage [<0.5 mg/day]). At an average dosage of 2.5 mg/day, patients initiating SCS started yielding a doubling of HCRU outcomes compared with patients not initiating SCS. Exposure to SCS at an average dosage of ≥ 7.5 mg/day resulted in 2.3-3.0 times greater HCRU from adverse outcomes compared with no exposure (Table 2).

3.3 | Healthcare resource utilization-associated costs

All-cause (excluding asthma) costs associated with adverse outcomes remained constant over the follow-up period in the non-SCS arm, but these costs increased over time in the SCS arm (Figure S3). Incremental all-cause adverse outcome-associated yearly costs for SCS patients were 7% greater in the first year and 50%, 70%, and 110% greater by Years 5, 10, and 15, respectively. Similar patterns were observed for asthma-related costs, although they were not as striking (Figure S3). When SCS use was categorized by mean average daily exposure (eg, >0 - <0.5 mg), similar all-cause adverse outcome-associated and asthma-related costs patterns to the overall SCS patients were observed (data not shown).

Compared with no SCS exposure, SCS use was associated with greater all-cause adverse outcome-associated healthcare costs (adjusted cost ratio [95% CI]: 1.16 [1.10-1.23], $P < 0.001$) and asthma-related healthcare costs (2.21 [2.13-2.29], $P < 0.001$) (Figure 2A). Adverse outcome-related cost differences were largest for pneumonia, and overall costs were about 2.3 times greater for the SCS arm than the non-SCS arm. Associated average annual costs for adverse outcomes and asthma were £1483 and £403 for SCS patients compared with £1165 and £166 for non-SCS patients, representing 42% greater overall costs, respectively. Among the adverse outcome-associated costs, key cost drivers were cardiovascular diseases, dialysis, and pneumonia.

There was a positive dosage-response association between the SCS exposure and adverse outcome-associated annual costs. The cost ratio (95% CI) was 1.25 (1.18-1.31) for 0.5- <2.5 mg/day, 1.78 (1.58-2.00) for 2.5- <5.0 mg/day, 2.27 (1.53-3.36) for 5.0- <7.5 mg/day, 2.41 (2.02-2.88) for 7.5- <15.0 mg/day, and 3.86 (2.53-5.89) for ≥ 15.0 mg/day for the SCS arm compared with the non-SCS arm. Hospitalization and prescriptions were the largest contributors to HCRU differences; cost ratio (95% CI) was 4.92 (2.70-8.97) for hospitalization and 8.12 (3.93-16.75) for prescriptions in the SCS arm exposed to an average daily dosage of ≥ 15 mg (all P -values <0.001) (Figure 2B). We observed doubling of non-SCS arm annual risk outcome-associated costs in the SCS arm starting at 2.5 mg/day (Table 3, Figure 3). Patients who were exposed to ≥ 7.5 mg/day SCS had a £3226 annual cost of adverse outcomes and a £1188 annual cost of asthma, which combined was 3.3 times greater than for non-SCS patients.

We found that when compared with patients who were exposed predominantly to acute SCS dosages (those in the lowest quartile of




FIGURE 1 Incidence rate ratio of HCRU for all SCS-related adverse outcomes^a by SCS status and average daily exposure^b. ^aExcluding asthma. Error bars represent 95% confidence interval. For adjustment, age and sex were used as forced covariates, with BMI, smoking status, antibiotic-treated infections, airflow limitation, asthma medication used (general and specified), intensive care unit stay, mechanical ventilation usage, and diagnosis of and/or treatment for diseases (Table S6) selected based on their incremental bias potential. ^bReference categories for daily exposure were for the lowest dosage (<0.5 mg/day). A&E, accident and emergency; BMI, body mass index; GP, general practice; SCS, systemic corticosteroids [Colour figure can be viewed at wileyonlinelibrary.com]

the refill rate), patients most likely on maintenance dosages of SCS (those in the highest quartile of the refill rate) incurred greater costs. Thus, maintenance SCS use seems to be associated with greater costs compared with acute SCS use (data not shown).

4 | DISCUSSION

In this report, we present the longitudinal effects of SCS treatment, irrespective of duration or dosage, on adverse outcomes, HCRU, and healthcare costs. This study was distinct from previous studies in terms of the availability of data prior to index date (50% with

≥8 years of data), allowing for a more accurate assessment of baseline SCS use and therefore identification of SCS initiators, and the long duration of its follow-up period. We found a dose-dependent increase in adverse outcomes, HCRU, and healthcare costs associated with SCS usage. To the best of our knowledge, this is the first study to report the long-term ramifications of SCS usage, both acute and long-term, on these parameters and to present these results as a function of SCS dosage.

Patients with severe, uncontrolled asthma are more likely to use OCS frequently than patients with moderate disease.^{16,17} Approximately 30%-40% of patients with severe asthma regularly use OCS to control their disease (intermittently or long term).¹⁶⁻²⁰ Prior




FIGURE 2 Association of all-cause adverse outcome^a-related costs with SCS status and average daily exposure. ^aExcluding asthma. Error bars represent 95% confidence interval. For adjustment, age and sex were used as forced covariates, with BMI, smoking status, antibiotic-treated infections, airflow limitation, asthma medication used (general and specified), intensive care unit stay, mechanical ventilation usage, and diagnosis of and/or treatment for diseases (Table S6) selected based on their incremental bias potential. BMI, body mass index; SCS, systemic corticosteroids [Colour figure can be viewed at wileyonlinelibrary.com]

studies have indicated an increased risk of adverse outcomes associated with SCS use, but none have used longitudinal data to quantify cumulative incidence.

We found that SCS initiation compared with non-SCS initiation is associated with substantially greater cumulative incidence of adverse outcomes, resulting in greater healthcare burden, and there is a positive dosage-response relationship between cumulative incidence of adverse outcomes and amount of SCS exposure. Increased risks of adverse outcomes over time means that SCS use can accrue a considerable, long-term healthcare burden.

Using British Thoracic Society treatment guidelines of 30 mg/day for 14 days per exacerbation, we estimated that patients with severe asthma (assumed to have had ≥3 exacerbations in a year without

long-term SCS use) are exposed to 1.26 g of corticosteroids per year (or 3.45 mg/day).²¹ Even with three steroid bursts per year, over the long term, these patients would have elevated risks of developing type 2 diabetes, osteoporosis, cataracts, or having at least one cardio-cerebrovascular disease episode. This circumstance represents a tremendous long-term public health issue and healthcare burden associated with SCS use. Clinicians should therefore consider treating their patients with steroid-sparing agents to reduce the risks associated with SCS use.

Although previous studies documented increased risks of corticosteroid-related onset of chronic complications, they examined different patient populations. Previous studies also did not explore the effect of dosage and duration of SCS exposure on chronic disease

TABLE 3 Mean (SD) annualized costs per patient for all-cause adverse outcomes and asthma (2016 £)

HCRU	No SCS n = 9413	Overall SCS n = 9413	Mean average daily exposure (mg/day)						≥15.0 n = 20
			>0-<0.5 n = 5152	0.5-<2.5 n = 3497	2.5-<5.0 n = 436	5.0-<7.5 n = 174	7.5-<15.0 n = 134		
All-cause adverse outcome-associated costs (excluding asthma-related costs)									
All resources	1164.83 (5756.23)	1483.03 (2294.54)	1209.53 (1844.68)	1610.17 (2110.54)	2427.65 (2743.92)	3116.72 (7560.37)	3043.43 (2893.84)	4448.53 (4573.52)	
General practitioner visits	330.58 (285.24)	447.26 (327.93)	379.89 (289.26)	496.42 (326.43)	631.56 (383.99)	713.26 (453.90)	723.35 (436.64)	1024.11 (618.45)	
Specialist visits	137.22 (263.90)	171.34 (290.09)	151.37 (259.83)	180.99 (296.27)	225.80 (331.58)	297.36 (514.45)	317.61 (413.26)	362.79 (689.25)	
Hospitalizations	592.59 (5503.01)	726.57 (1851.15)	558.52 (1359.46)	792.17 (1649.88)	1343.17 (2152.16)	1812.85 (7376.75)	1779.20 (2472.25)	2598.14 (3515.41)	
Accident and emergency visits	21.05 (89.26)	28.15 (70.83)	25.14 (66.04)	31.34 (74.51)	31.19 (75.80)	28.36 (54.61)	36.49 (87.17)	124.50 (248.74)	
Prescriptions	83.60 (396.81)	110.19 (496.75)	95.07 (524.69)	109.11 (361.91)	197.96 (740.22)	268.56 (1008.97)	191.03 (314.86)	362.46 (628.34)	
Asthma-related HCRU costs									
All resources	166.39 (209.56)	402.93 (478.31)	272.98 (269.88)	493.08 (487.28)	785.76 (731.03)	784.56 (915.05)	1077.87 (1296.15)	1925.37 (1347.81)	
General practitioner visits	48.16 (52.39)	95.24 (72.77)	72.21 (53.12)	115.70 (72.15)	152.45 (103.57)	159.73 (119.64)	157.30 (117.03)	225.20 (127.72)	
Specialist visits	10.27 (91.20)	36.64 (160.08)	18.80 (65.32)	40.67 (138.38)	109.19 (252.66)	142.19 (676.96)	177.32 (279.09)	486.79 (1083.06)	
Hospitalizations	2.99 (45.60)	46.86 (291.06)	14.47 (95.46)	68.66 (356.00)	126.68 (456.66)	98.34 (439.26)	296.76 (1011.61)	717.26 (925.33)	
Accident and emergency visits	0.22 (2.91)	1.36 (10.67)	0.82 (7.18)	1.85 (12.42)	2.77 (14.20)	0.55 (5.41)	4.91 (39.36)	7.49 (30.77)	
Prescriptions	106.08 (145.53)	226.72 (224.12)	170.41 (190.93)	270.51 (214.07)	397.81 (290.03)	386.63 (279.12)	444.47 (406.66)	492.93 (405.04)	

BMI, body mass index; SCS, systemic corticosteroids; SD, standard deviation.




FIGURE 3 Mean annualized all-cause adverse outcome-associated^a cost.

^aExcluding asthma. Error bars represent 95% confidence interval. BMI, body mass index; SCS, systemic corticosteroids [Colour figure can be viewed at wileyonlinelibrary.com]

onset, associated disease prevalence, and HCRU and costs for patients with asthma.²²⁻²⁶ Sullivan et al²² observed an increase in the odds ratio of new adverse events combined with greater SCS use (1.04 vs 1.29 for 1-3 vs ≥ 4 prescriptions within the year), consistent with our findings for individual adverse events. In the Zazzali et al²³ study, increased healthcare utilization and adverse events associated with SCS use were reported, with adverse events further stratified by the presence of chronic obstructive pulmonary disease. Hypertension and type 2 diabetes were the most common SCS-associated adverse events that were more prevalent in this group than in the non-SCS group (62.9% vs 56.9% and 34.0% vs 28.4%, respectively). Effect of cumulative SCS dosage was not reported. Barry et al²⁴ estimated the increased costs of SCS-related morbidity, and O'Neill et al²⁶ estimated cost differences for patients using maintenance steroids vs those not on maintenance steroids. Neither study, however, collected information on initiation of treatment or cumulative dosage. Other prior studies that examined HCRU and costs did so over an average of 2 years, while previous studies on clinical outcomes related to SCS exposure only considered an average exposure period of 6 months and none investigated the impact of lifetime exposure. Unlike other studies,²²⁻²⁶ our study was based on a large cohort of patients initiating SCS and explored the long-term impact of SCS exposure. Our study had a greater amount of medical record history available (≥ 4 years for $>75\%$ of patients and ≥ 8 years for 50% of patients) than previous studies (≤ 2 years),^{23,24,26} resulting in a more accurate determination of prior SCS exposure. To accurately assess the impact of SCS-associated adverse outcomes on patients, we excluded patients with adverse outcomes prior to index date (or first SCS dose). Patients in our analyses had an average of 8.6 years of follow-up in the SCS arm and an average of 7.7 years in the non-SCS arm. The average age of our study patient population was 46 years, consistent with other asthma study patient populations.^{6,10,18}

Our study is the first to demonstrate that the costs associated with SCS-associated adverse outcomes increased over the years

according to SCS exposure, both overall and by SCS dosage. Incremental yearly costs for SCS patients were 7% greater in the first year and 1.5, 1.7, and 2.2 times greater by Years 5, 10, and 15, respectively. This is consistent with incremental cumulative incidence of the adverse outcomes in the SCS arm. Even though we also observed slight increases in the adverse outcome cumulative incidence in the non-SCS arm, their longitudinal annual costs remained flat, hinting potentially that the adverse outcomes observed in the SCS arm could be more severe.

A UK study comparing nonasthma control (no exposure) with GINA Step 2/3 patients (low exposure) and GINA Step 5 patients (high exposure) estimated the annual cost (2013 values) of corticosteroid-induced morbidity was £224 for low-exposed group and £1310 for high-exposed group.²⁵ It is unclear what the dosages were in a study by Berry et al.²⁵ In our study, we observed a £44.70, £445.34, £1262.82, £1951.89, £1878.60, and £3283.70 incremental SCS adverse outcome-associated average annual cost for SCS exposure of 0.5-<2.5 mg/day, 2.5-<5.0 mg/day, 5.0-<7.5 mg/day, 7.5-<15.0 mg/day, and ≥ 15.0 mg/day, respectively.

4.1 | Limitations

This study has several limitations. Although confounding by all measured patient characteristics was considered and addressed, as in all observational research, we cannot exclude confounding by characteristics we did not measure. As patients receiving SCS may be more likely to be screened for comorbidities, an overestimation of comorbidities in this group relative to the non-SCS group may have occurred.

When looking at the different resource types, we observed a low frequency of specialist consultations and A&E attendance. In the UK healthcare system, chronic diseases are typically managed under primary care, and there is a clear tendency toward keeping as much health care as possible at the primary care level. Therefore, our HCRU results underestimated the burden that may be carried under

secondary or specialist care, where we could observe much greater HCRU-associated costs. This analysis excluded those who died due to the adverse outcomes prior to the 15-year mark and most likely underestimated incidence in the SCS arm more than in the non-SCS arm.

For calculating costs for HCRU, we considered just the most prevalent SCS-related adverse outcomes rather than all possibilities. Weight gain was identified as one of the key adverse outcomes for SCS exposure. However, we could not link weight gain to any specific HCRU-related outcomes to account for the cost. Therefore, an inability to account for adverse health effects such as weight gain led to the underestimation of the SCS burden.

We have considered a large set of covariates as potential confounders in the models. However, it is possible that information on confounding factors was not available to use. The data we used were registered during regular care, and not for research purposes. As a result, disease history and onset could have been recorded incorrectly or not at all. These input-related variations could have led to over- or underestimation of the observed associations.

5 | CONCLUSIONS

Our study is the first long-term follow-up study to examine SCS adverse outcome burden and document the longitudinal detrimental effect of SCS exposure among SCS initiators. We observed an increase in cumulative incidence of adverse outcomes and associated healthcare costs over time for SCS-exposed patients. A positive dosage–response relationship was observed between average daily SCS exposure and cumulative SCS adverse outcomes incidence, associated HCRU, and healthcare costs. Even low-grade exposure to SCS was related to long-term detrimental effects of adverse outcomes.

ACKNOWLEDGMENTS

Editorial support was provided by Mike Jaqua, PhD, and Alan Saltzman, PhD, of JK Associates, Inc., and Michael A. Nissen, ELS, of AstraZeneca. This support was funded by AstraZeneca.

CONFLICTS OF INTEREST

Jaco Voorham and Marjan Kerkhof are current employees of the Observational and Pragmatic Research Institute, which has conducted paid research in respiratory disease on behalf of the following organizations in the past 5 years: Aerocrine, AKL Research and Development Ltd, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Orion, Takeda, Teva, Zentiva (a Sanofi company). Joanna Zhi Jie Ling and Mandy Ow were former employees of the Observational and Pragmatic Research Institute at the time of the study. David B. Price has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim,

Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva (Sanofi Generics); payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Skyepharma, Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, Zentiva (Sanofi Generics); stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment. Xiao Xu, Sarwar Golam, Jill Davis, and Trung N. Tran are employees of AstraZeneca.

AUTHOR CONTRIBUTION

All authors participated in the conception and design of the study; the acquisition, analysis and interpretation of the data; the preparation, review, and revision of the manuscript; and the approval to submit.

ORCID

David B. Price  <http://orcid.org/0000-0002-9728-9992>

REFERENCES

1. Amelink M, Hashimoto S, Spinhoven P, et al. Anxiety, depression and personality traits in severe, prednisone-dependent asthma. *Respir Med*. 2014;108:438-444.
2. Iribarren C, Tolstykh IV, Miller MK, Sobel E, Eisner MD. Adult asthma and risk of coronary heart disease, cerebrovascular disease, and heart failure: a prospective study of 2 matched cohorts. *Am J Epidemiol*. 2012;176:1014-1024.
3. Lefebvre P, Duh MS, Lafeuille MH, et al. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. *J Allergy Clin Immunol*. 2015;136:1488-1495.
4. Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. *Respir Med*. 2009;103:975-994.
5. Dean GE. Editorial comment. *J Urol*. 2009;182(Supplement 4):1763-1764.

6. Hyland ME, Whalley B, Jones RC, Masoli M. A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales. *Qual Life Res.* 2015;24:631-639.
7. Walsh LJ, Wong CA, Osborne J, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. *Thorax.* 2001;56:279-284.
8. Dalal AA, Duh MS, Gozalo L, et al. Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma. *J Manag Care Spec Pharm.* 2016;22:833-847.
9. Weiss AJ, Elixhauser A, Bae J, Encinosa W. Origin of Adverse Drug Events in U.S. Hospitals, 2011: Statistical Brief #158. Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality. <https://www.hcup-us.ahrq.gov/reports/statbriefs/sb158.jsp>. Accessed December 12, 2017.
10. Kerkhof M, Tran TN, Soriano JB, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. *Thorax.* 2018;73:116-124.
11. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). *Int J Epidemiol.* 2015;44:827-836.
12. Curtis LB, Burns A. Unit Costs of Health and Social Care 2015. Personal Social Services Research Unit. <http://www.pssru.ac.uk/pub/uc/uc2015/full.pdf>. Accessed October 25, 2017.
13. Department of Health NHS England. Reference Costs 2015-16. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/577083/Reference_Costs_2015-16.pdf. Accessed October 25, 2017.
14. NHS Dictionary of Medicines and Devices 2017. <http://dmd.medicines.org.uk/>. Accessed November 27, 2017.
15. Dr. Foster® intelligence. Understanding HSMRs. A toolkit on hospital standardised mortality ratios. http://www.drfooster.com/wp-content/uploads/2014/09/HSMR_Toolkit_Version_9_July_2014.pdf. Accessed November 17, 2017.
16. Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. *Eur Respir J.* 2004;23:723-729.
17. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. *J Allergy Clin Immunol.* 2007;119:405-413.
18. ENFUMOSA. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. *Eur Respir J.* 2003;22:470-477.
19. Heaney LG, Brightling CE, Menzies-Gow A, Stevenson M, Niven RM, British Thoracic Society Difficult Asthma Network. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. *Thorax.* 2010;65:787-794.
20. van der Molen T, Ostrem A, Stallberg B, Ostergaard MS, Singh RB. International Primary Care Respiratory Group (IPCRG) Guidelines: management of asthma. *Prim Care Respir J.* 2006;15:35-47.
21. British Thoracic Society. British Guideline on the Management of Asthma: a National Clinical Guideline 2009. <https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2009/>. Accessed October 25, 2017.
22. Sullivan PW, Ghushchyan VA, Globe G, Schatz M. Oral corticosteroid exposure and adverse effects in asthmatic patients. *J Allergy Clin Immunol.* 2018;141:110-116.
23. Zazzali JL, Broder MS, Omachi TA, Chang E, Sun GH, Raimundo K. Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use. *Allergy Asthma Proc.* 2015;36:268-274.
24. Barry LE, Sweeney J, O'Neill C, Price D, Heaney LG. The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis. *Respir Res.* 2017;18:129.
25. Berry JG, Rodean J, Hall M, et al. Impact of chronic conditions on emergency department visits of children using Medicaid. *J Pediatr.* 2017;182:267-274.
26. O'Neill S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. *Thorax.* 2015;70(4):376-378.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Voorham J, Xu X, Price DB, et al. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. *Allergy.* 2019;74:273–283. <https://doi.org/10.1111/all.13556>